Drug interactions with carbamazepine: a case study of influence on anticoagulation treatment with warfarin
Abstract
Background: Drug interactions are an important segment of drug related problems. Therefore their evaluation should be an integral component of patient management, especially in elderly patients who often receive multiple medications. In this manuscript drug interactions with emphasis on their relevance and mechanism are reviewed. Additionally, as an example a detailed analysis of induction of warfarin metabolism during co-treatment with carbamazepine is presented.
Patients and methods: We searched MEDLINE and tertiary sources. 188 patients on warfarin therapy in the maintenance phase were retrospectively analysed to study the interaction of carbamazepine with warfarin. Blood plasma concentrations of warfarin enantiomers and their metabolites were measured by high performance liquid chromatography.
Results: In patients co-treated with carbamazepine daily warfarin dose necessary to maintain INR in the range between 2.0 in 3.0 was significantly higher (9.00 versus 4.07 mg/day). Despite the difference in daily dose requirement plasma concentrations of warfarin enantiomers were similar, due to the enhanced metabolism of predominantly R-warfarin by cytochrome P450 (CYP) 3A4. Consequently, the concentration of 10-hydroxywarfarin, which is formed by CYP3A4 was 9-times higher.
Conclusions: With this study relevance and mechanism of carbamazepine interaction with warfarin was assessed. The study confirmed that the need for warfarin dosage adjustment during initiation and discontinuation of carbamazepine treatment is caused by induction of warfarin metabolism, predominantly by CYP3A4.
Downloads
References
Naismyth JG. The Antagonism of Opium and Belladonna, Illustrated by a Case of Attempted Suicide. J Anat Physiol 1880; 14: 449-51.
Note for guidance on the investigation of drug interactions 1997. The European Agency for the Evaluation of Medicinal Products.
Tatro DS. Drug interaction facts: The authority on drug interactions. St. Louis, MO: Facts and Comparisons; 2006.
Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc (Wash) 2002; 42: 439-48.
Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; 2: 564-7.
Tršinar M, Vovk T. Interakcije med zdravili za starostnike-teoretičen in praktičen vidik / Drug interactions in the elderly-theoretical and practical view. Farm Vest 2005; 56: 89-96.
Alfaro CL, Piscitelli SC. Drug interactions. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, eds. Principles of clinical pharmacology. San Diego: Academic Press; 2001. p. 16780.
Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (Wash DC) 2004; 44: 136-41.
Martin U, Prescott LF. The interaction of paracetamol with frusemide. Br J Clin Pharmacol 1994; 37: 464-7.
Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999; 39: 1109-25.
Piscitelli SC, Goss TF, Wilton JH, D’Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991; 35: 1765-71.
Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21.
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-90.
Flockhart DA. Cytochrome P450 druginteraction table. Available from: http://medicine.iupui.edu/flockhart/
Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109: 481-8.
Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41: 1633-52.
Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37: 563-9.
Park BK. Warfarin: metabolism and mode of action. Biochem Pharmacol 1988; 37: 19-27.
Toon S, Low LK, Gibaldi M, Trager WF, O’Reilly RA, Motley CH, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986; 39: 15-24.
Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
Lal S, Jada SR, Xiang X, Lim WT, Lee EJ, Chowbay B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin Pharmacokinet 2006; 45: 1189-200.
USP DI Volume I: Drug Information for the Health Care Professional., Thomson Micromedex; 2004. p. 709-16.
Gidal BE, Garnett WR. Epilepsy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill; 2005. p. 1023-48.
Bauer LA. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2005. p. 500-15.
Prescribing information for Tegretol CR400® tablets.
Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.
Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 7827.
Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, et al. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006; 62: 291-6.
Locatelli I, Kmetec V, Mrhar A, Grabnar I. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818: 191-8.
Parrish RH, Pazdur DE, O’Donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. Pharmacotherapy 2006; 26: 1650-3.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
